Neurocrine Biosciences (NBIX) Receivables - Net (2017 - 2025)
Neurocrine Biosciences (NBIX) has disclosed Receivables - Net for 15 consecutive years, with $686.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 43.35% year-over-year to $686.8 million, compared with a TTM value of $686.8 million through Dec 2025, up 43.35%, and an annual FY2025 reading of $686.8 million, up 43.35% over the prior year.
- Receivables - Net was $686.8 million for Q4 2025 at Neurocrine Biosciences, down from $728.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $728.0 million in Q3 2025 and bottomed at $147.8 million in Q1 2021.
- Average Receivables - Net over 4 years is $434.1 million, with a median of $450.7 million recorded in 2024.
- The sharpest move saw Receivables - Net fell 0.54% in 2021, then skyrocketed 51.32% in 2025.
- Year by year, Receivables - Net stood at $163.8 million in 2021, then skyrocketed by 168.19% to $439.3 million in 2023, then grew by 9.06% to $479.1 million in 2024, then soared by 43.35% to $686.8 million in 2025.
- Business Quant data shows Receivables - Net for NBIX at $686.8 million in Q4 2025, $728.0 million in Q3 2025, and $595.7 million in Q2 2025.